• 1
    Madigan MP, Ziegler RG, Benichou J, Byrne C, Hoover RN. Proportion of breast cancer cases in the United States explained by well-established risk factors. J Natl Cancer Inst. 1995; 87: 16811685.
  • 2
    Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet. 1995; 57: 14571462.
  • 3
    Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999; 340: 7784.
  • 4
    Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001; 93: 16331637.
  • 5
    King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001; 286: 22512256.
  • 6
    Warner E, Plewes DB, Shumak RS, et al. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol. 2001; 19: 35243531.
  • 7
    Friedenson B. Is mammography indicated for women with defective BRCA genes? Implications of recent scientific advances for the diagnosis, treatment, and prevention of hereditary breast cancer. MedGenMed. 2000; 2: E9.
  • 8
    Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin. 2003; 53: 2743.
  • 9
    Houssami N, Irwig L, Simpson JM, McKessar M, Blome S, Noakes J. Sydney Breast Imaging Accuracy Study: comparative sensitivity and specificity of mammography and sonography in young women with symptoms. AJR Am J Roentgenol. 2003; 180: 935940.
  • 10
    Saarenmaa I, Salminen T, Geiger U, et al. The effect of age and density of the breast on the sensitivity of breast cancer diagnostic by mammography and ultasonography. Breast Cancer Res Treat. 2001; 67: 117123.
  • 11
    Tilanus-Linthorst MM, Obdeijn IM, Bartels KC, de Koning HJ, Oudkerk M. First experiences in screening women at high risk for breast cancer with MR imaging. Breast Cancer Res Treat. 2000; 63: 5360.
  • 12
    Kuhl CK, Schmutzler RK, Leutner CC, et al. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology. 2000; 215: 267279.
  • 13
    Tilanus-Linthorst M, Verhoog L, Obdeijn IM, et al. A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int J Cancer. 2002; 102: 9195.
  • 14
    Harms SE, Flamig DP. MR imaging of the breast: technical approach and clinical experience. Radiographics. 1993; 13: 905912.
  • 15
    Cross M, Harms SE, Cheek JH, Peters GN, Jones RC. New horizons in the diagnosis and treatment of breast cancer using magnetic resonance imaging. Am J Surg. 1993; 166: 749753; discussion, 753–755.
  • 16
    Kaiser WA. [Magnetic resonance tomography of the breast. The results of 253 examinations]. Dtsch Med Wochenschr. 1989; 114: 13511357.
  • 17
    Orel SG. High-resolution MR imaging of the breast. Semin Ultrasound CT MR. 1996; 17: 476493.
  • 18
    Robson ME, Morris E, Kauff N, et al. Breast cancer screening utilizing magnetic resonance imaging (MRI) in carriers of BRCA mutations [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 362a.
  • 19
    Kuhl CK, Schrading S, Leutner CC, et al. Surveillance of “high risk” women with proven or suspected familial (hereditary) breast cancer: first mid-term results of a multi-modality clinical screening trial [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 4a.
  • 20
    Kriege M, Brekelmans CT, Boetes C, et al. MRI screening for breast cancer in women with high familial and genetic risk: first results of the Dutch MRI screening study (MRISC) [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 5a.
  • 21
    Trecate G, Vergnaghi D, Bergonzi S, et al. BMRI in early detection of breast cancer in patients with increased genetic risk: our preliminary results. J Exp Clin Cancer Res. 2002; 21(3 Suppl ): 125130.
  • 22
    Trecate G, Vergnaghi D, Bergonzi S, et al. Breast MRI screening in patients with increased familial and/or genetic risk for breast cancer: a preliminary experience. Tumori. 2003; 89: 125131.
  • 23
    Podo F, Sardanelli F, Canese R, et al. The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. J Exp Clin Cancer Res. 2002; 21(3 Suppl ): 115124.
  • 24
    Leach MO, Eeles RA, Turnbull LW, et al. The UK national study of magnetic resonance imaging as a method of screening for breast cancer (MARIBS). J Exp Clin Cancer Res. 2002; 21(3 Suppl ): 107114.
  • 25
    Stoutjesdijk MJ, Boetes C, Jager GJ, et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst. 2001; 93: 10951102.
  • 26
    Plevritis SK, Ikeda DM. Ethical issues in contrast-enhanced magnetic resonance imaging screening for breast cancer. Top Magn Reson Imaging. 2002; 13: 7984.
  • 27
    Wrensch M, Petrakis NL, King EB, Lee MM, Milke R. Breast cancer risk associated with abnormal cytology in nipple aspirates of breast fluid and prior history of breast biopsy. Am J Epidemiol. 1993; 137: 829833.
  • 28
    Fabian CJ, Kimler BF, Zalles CH. Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst. 2000; 92: 12171227.
  • 29
    Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst. 1997; 89: 227238.
  • 30
    Claus EB, Risch N, Thompson WB. The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Res Treat. 1993; 28: 115120.
  • 31
    Parmigiani G, Berry DA, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998; 62: 145158.
  • 32
    Agoston AT, Daniel B, Herfkens RJ, et al. Intensity-modulated parametric mapping for simultaneous display of rapid dynamic and high-spatial-resolution breast MR imaging data. Radiographics. 2001; 21: 217226.
  • 33
    Yen YF, Han K, Daniel BL, et al. Dynamic breast MRI with spiral trajectories: 3D versus 2D. J Magn Reson Imaging. 2000; 11: 351359.
  • 34
    Leong CS, Daniel BL, Herfkens RJ, et al. Characterization of breast lesion morphology with 3DSSMT: an adjunct to dynamic breast MRI. J Magn Reson Imaging. 2000; 11: 8796.
  • 35
    Daniel BL, Yen YF, Glover GH, et al. Breast disease: dynamic spiral MR imaging. Radiology. 1998; 209: 499509.
  • 36
    Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002; 346: 16161622.
  • 37
    Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002; 346: 16091615.
  • 38
    Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet. 2000; 356: 18761881.
  • 39
    Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer. 1985; 55: 26982708.
  • 40
    Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989; 81: 18791886.
  • 41
    Kauff ND, Brogi E, Scheuer L, et al. Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer. 2003; 97: 16011608.
  • 42
    Hoogerbrugge N, Bult P, de Widt-Levert LM,et al. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol. 2003; 21: 4145.
  • 43
    Khan SA, Rodriguez N, Baird C, et al. Ductal lavage findings in women with known breast cancer undergoing mastectomy [abstract]. Presented at the 25th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 10–13, 2001.
  • 44
    Dooley WC, Ljung BM, Veronesi U, et al. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst. 2001; 93: 16241632.
  • 45
    Sidawy MK, Stoler MH, Frable WJ, et al. Interobserver variability in the classification of proliferative breast lesions by fine-needle aspiration: results of the Papanicolaou Society of Cytopathology Study. Diagn Cytopathol. 1998; 18: 150165.